Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.
Andrew C JohnsMike YangLai WeiMadison GroganSandipkumar H PatelMingjia LiMarium HusainKari L KendraGregory A OttersonJarred T BurkartDaniel J SpakowiczRebecca HoydDwight H OwenCarolyn J PresleyPublished in: Cancer immunology, immunotherapy : CII (2023)
No specific MC predicted risk of irAEs or OS for patients receiving IO. Increased CCI score did not predict risk of irAEs but was associated with shorter OS. This suggests IO is safe for patients with MC, but MC may limit survival benefits of IO. CVD may predict shorter OS in patients with irAEs and should be evaluated among patients receiving IO.